Masimo Corp - MASI STOCK NEWS

Masimo's Signal Extraction Technology® (SET®) pulse oximetry continues to lead the industry with superior accuracy and reliability. As of 2024, SET® is the primary pulse oximetry technology at all ten top U.S. hospitals and monitors over 200 million patients annually worldwide. With more than 100 clinical studies demonstrating its performance, SET® offers industry-best SpO2 accuracy in challenging conditions across all patient populations and skin tones.

Masimo SET® has shown significant improvements in patient outcomes, including zero preventable deaths from opioid-induced respiratory depression in a 10-year study, 80% reduction in retinopathy of prematurity, and improved screening for critical congenital heart disease. It also reduces false alarms by 86% and has led to 60% fewer rapid response team activations. Additionally, SET® contributes to environmental sustainability and cost savings for hospitals.

Masimo (NASDAQ: MASI) has filed revised definitive proxy materials for its upcoming Annual Meeting of Stockholders on September 19, 2024. The company urges stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card. Masimo reported strong second quarter results, including:

- Healthcare segment revenue growth of 23% year-over-year
- Record-breaking new hospital conversion contracts worth $134 million
- Improved healthcare gross margin by 240 basis points year-over-year
- Generated $75 million in operating cash flow
- Retired $93 million of outstanding debt

The company raised its full-year guidance for healthcare revenue growth to 9-10% and reaffirmed its commitment to separating its consumer business. Masimo aims to double earnings per share to $8 in five years and eliminate debt within 3-4 years.

Masimo (NASDAQ: MASI) announced FDA 510(k) clearance for the Masimo W1® medical watch's connectivity to the Masimo SafetyNet® telemonitoring system. This integration allows continuous, accurate wrist-based measurements to be relayed to caregivers via the Masimo Secure Health Data Cloud. The Masimo W1 Medical, which received FDA clearance last year for continuous SpO2 and pulse rate monitoring, can now transmit data to the SafetyNet smartphone app and web-based clinician portal.

The Masimo W1 features the MW-1 sensor module, incorporating Signal Extraction Technology® pulse oximetry and rainbow® Pulse CO-Oximetry. It offers real-time display of SpO2, pulse rate, perfusion index, and ECG-derived heart rate. With Bluetooth connectivity, patients can input symptoms, view data trends, and conduct virtual visits through the SafetyNet app. Clinicians can access patient data, receive customized notifications, and integrate information into EMRs.

Masimo (NASDAQ: MASI) reported its financial results for Q2 2024, ending June 29, 2024. Consolidated revenue reached $496.3 million, comprising healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million.

Consolidated GAAP net income was $16.0 million, or $0.29 per diluted share, while non-GAAP net income was $46.6 million, or $0.86 per diluted share.

Based on this performance, Masimo is raising its full-year 2024 guidance: consolidated revenue forecasted between $2,085 to $2,135 million and consolidated EPS between $3.80 to $4.00.

A new study published in the Journal of Orthopaedics reveals that remote patient monitoring (RPM) using Masimo SafetyNet® significantly reduced hospital readmission and ED visit rates for patients recovering at home after joint replacement surgery. The research, conducted at St. Luke's University Health Network, compared 50 patients using RPM to 50 without RPM. Key findings include:

- RPM group: 20% had abnormal vital signs, 4% visited ED, 0% readmitted
- Control group: 12% visited ED, all resulting in hospital readmission
- Estimated potential savings of $800,000 per 1,000 surgeries
- 79% of RPM patients felt safer and would recommend the system

The study concludes that RPM is a feasible way to mitigate readmissions and increase patient satisfaction in outpatient total joint arthroplasty.

Masimo (NASDAQ: MASI) has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after the market closes. The results will cover the period ended March 30, 2024. A conference call and webcast to discuss the results will begin at 1:30 p.m. PT (4:30 p.m. ET) on the same day.

The call will be hosted by Joe Kiani, Chairman and CEO, and Micah Young, Executive VP and CFO. Interested parties can register for the call using the provided link to receive dial-in details and a registrant ID. A replay of the webcast and conference call will be available shortly after the conclusion and archived on Masimo's website.

Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has responded to the company's decision to delay its Annual Meeting from July 25 to September 19, 2024. Politan views this as an entrenchment maneuver by CEO Joe Kiani to prevent shareholders from being heard. The delay pushes the meeting beyond the 13-month limit required by Delaware law.

Politan also addressed a lawsuit filed against them by Masimo's Board, calling it retaliatory and meritless. They plan to take action to ensure the meeting is not delayed further and potentially held sooner. Politan encourages shareholders to vote for their nominees, Darlene Solomon and William Jellison, on the WHITE proxy card to support change at Masimo.

Masimo (Nasdaq: MASI) has initiated legal action against Politan Capital Management LP, seeking to compel Politan to rectify material misstatements and omissions in their proxy materials. The complaint alleges that Quentin Koffey has aided plaintiff's counsel in litigation against Masimo. In response to these developments and a request from Politan, Masimo has rescheduled its 2024 Annual Meeting of Stockholders to September 19, 2024, at 2:00 p.m. PDT, with a new record date of August 12, 2024. This postponement aims to ensure a fair and fully informed stockholder vote. Masimo will file a revised proxy statement and conduct a new broker search. All stockholders, including those who previously voted, will need to resubmit their votes based on the updated information.

Masimo (NASDAQ: MASI) responds to Politan's misrepresentations, addressing key issues:

• Joint Venture (JV): The proposed JV won't compete with Masimo in healthcare or benefit CEO Joe Kiani at shareholders' expense. Kiani commits to not supporting the JV unless the entire Board, including Politan's Quentin Koffey, approves.
• Director Independence: Masimo asserts its directors are truly independent, contrary to Politan's claims.
• Healthcare Business Performance: Masimo highlights strong revenue growth and improving EBIT margins.
• Future Plans: Masimo aims for 30% EBIT margins and $8 EPS by 2029, while questioning Politan's ability to deliver greater value.
• Voting Practices: Masimo denies engaging in "empty voting".

Masimo urges shareholders to vote for Kiani and Christopher Chavez using the GOLD proxy card.